

ANALYSIS OF NON-BLEEDING UTERINE FIBROIDS SYMPTOM (NBUFSQ) QUESTIONNAIRE  
DURING TREATMENT AND POST-TREATMENT FOLLOW-UP PERIODS  
(MODIFIED INTENT-TO-TREAT ANALYSIS SET - COHORT 2)

				WITHIN GROUP			MODEL-BASED BETWEEN GROUP COMPARISON				
				----- CHANGE FROM BASELINE -----			----- COMPARE TO PLACEBO -----				
VARIABLE							DIFFERENCE				
TIME POINT		BASE	VISIT				LS		OF LS		
TREATMENT	N	MEAN	MEAN	MEAN	SD	95% CI	MEANS (SE)		MEANS (SE)	95% CI	P-VALUE \$
SUM OF SCORES OF Q1 TO Q6											
BASELINE											
PLACEBO	64		13.2				13.2 (1.64)				
ELAGOLIX 600 MG QD	73		17.7				17.7 (1.54)	4.5 (2.25)	(0.05, 8.90)		0.047*
ELAGOLIX 600 MG QD											
+E2/NETA (LD)	65		14.5				14.5 (1.63)	1.3 (2.31)	(-3.24, 5.86)		0.572
ELAGOLIX 600 MG QD											
+E2/NETA (SD)	72		13.2				13.2 (1.55)	0.1 (2.25)	(-4.37, 4.50)		0.977

FINAL MONTH #											
PLACEBO		66	13.2	12.5	-0.8	11.34	(-3.75, 2.11)	-1.3 (1.19)			
ELAGOLIX 600 MG QD		70	17.7	13.3	-4.0	9.40	(-6.33, -1.74)	-3.3 (1.13)	-2.0 (1.65)	(-5.26, 1.23)	0.223
ELAGOLIX 600 MG QD											
+E2/NETA (LD)		65	14.4	12.0	-3.3	8.09	(-5.42, -1.27)	-3.3 (1.18)	-2.1 (1.68)	(-5.38, 1.22)	0.215
ELAGOLIX 600 MG QD											
+E2/NETA (SD)		61	13.4	10.6	-2.3	10.56	(-4.98, 0.47)	-2.7 (1.19)	-1.4 (1.68)	(-4.75, 1.87)	0.392